Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277669 | 1.00 | CHRM2 (0.44) | CHRM2CHRM3SIGMAR1GAASCN5A | |
| SCHEMBL9000665 | 0.93 | CHRM2 (0.43) | CHRM2CHRM3SIGMAR1GAAMEN1 | |
| SCHEMBL11085392 | 0.86 | HTR2A (0.38) | CHRM2CHRM3SIGMAR1GAA | |
| SCHEMBL11483604 | 0.84 | HDAC3 (0.39) | CHRM2CHRM3GAA | |
| SCHEMBL12267888 | 0.82 | SCN5A (0.59) | CHRM3SCN5ASCN9AMEN1KMT2A | |
| SCHEMBL28983000 | 0.81 | SIGMAR1 (0.46) | CHRM2CHRM3SIGMAR1GAASCN5A | |
| SCHEMBL12099349 | 0.81 | CHRM2 (0.44) | CHRM2CHRM3SIGMAR1GAASCN5A | |
| SCHEMBL11480234 | 0.80 | LTA4H (0.49) | CHRM2CHRM3GAAMEN1KMT2A | |
| SCHEMBL31314899 | 0.78 | CHRM2 (0.46) | CHRM2CHRM3GAASCN5ASCN9A | |
| SCHEMBL29211131 | 0.78 | CHRM2 (0.46) | CHRM2CHRM3GAASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10159966-B2 | Catalyst complexes with carbene ligand and method for making same and use in metathesis reaction | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2018-12-25 | — | — | US | disclosed |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2015-12-24 | — | — | US | disclosed |
| EP-2943499-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | Guangming Innovation Company (Wuhan) (CN) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014108071-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | GUANG MING INNOVATION COMPANY (WUHAN) (CN) | 2014-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159966-B2 | Catalyst complexes with carbene ligand and method for making same and use in metathesis reaction | MSMO1, ALOX12, SQLE | CHRM2 434/4885CHRM3 611/4885SIGMAR1 1109/4885 |
| US-20150367338-A1 | CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION | MSMO1, ALOX12, SQLE | CHRM2 434/4885CHRM3 611/4885SIGMAR1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.